Navigation Links
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Date:5/31/2008

of patients, respectively), anemia (20 percent vs. 11 percent vs. 17 percent), neutropenia (15 percent vs. 22 percent vs. 26 percent) and asthenia (13 percent vs. 19 percent vs. 8 percent).

The clinical data for TORISEL presented at the meeting represent only a portion of the totality of the safety and efficacy data from the ongoing clinical development of TORISEL.

About TORISEL

TORISEL is an mTOR inhibitor. Inhibition of mTOR in treated cancer cells blocked the translation of genes that regulate the cell cycle. In in vitro studies using renal cancer cell lines, TORISEL inhibited the activity of mTOR and resulted in reduced levels of certain cell growth factors involved in the development of new blood vessels, such as vascular endothelial growth factor.

TORISEL is approved for the treatment of advanced RCC in the United States, European Union and other markets, based on results of a phase 3 clinical study that demonstrated that TORISEL improves overall survival for patients with advanced RCC compared with interferon-alpha.

An application for the use of TORISEL for the treatment of relapsed and/or refractory MCL is currently under review with the European Medicines Agency (EMEA). TORISEL received Orphan Medicinal Product designation for the treatment of MCL in the European Union in November 2006.

Important Safety Information

Hypersensitivity reactions manifested by symptoms, including, but not limited to anaphylaxis, dyspnea, flushing and chest pain have been observed with TORISEL.

Serum glucose, serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.

The use of TORISEL is likely to result in hyperglycemia and hyperlipemia. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy and/or lipid-lowering agents, respectively.

The use of TORISEL may result in immunosuppression. Patients should be
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
3. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
4. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
5. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
6. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
7. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
8. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
9. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
10. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
11. Tailored Clopidogrel Dosing Improves PCI Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... After 6 months of careful research ... - the new programme for the next Cool Chain & ... global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA and purchasing ... is broad and yet specific, focused and yet accessible, inclusive ...
(Date:9/18/2014)...  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical ... RNA viruses, today announced a research collaboration with ... testing of the Company,s lead compound, SB 9200, ... against which currently there are no effective antiviral ... proprietary Small Molecule Nucleic Acid Hybrid (SMNH) ...
(Date:9/18/2014)... ROCKVILLE, Md. , Sept. 18, 2014 ... a biotechnology company with fully integrated commercial and drug ... oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary focus on China , announce ...
Breaking Medicine Technology:Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
(Date:9/19/2014)... September 19, 2014 Yisrayl Hawkins, Pastor of ... expounding on the need to protect children. He begins by ... Michael Brown and reminds that there are many other children, ... says violence is spreading faster than cancer all over the ... “There are close to seven billion Michaels in the world ...
(Date:9/19/2014)... Los Angeles, California (PRWEB) September 19, 2014 ... a younger man for companionship and intimacy, and there are ... connection with an experienced, mature woman. SeekingCougar.com now ... , This online dating website caters to older women, and ... offers an easy and convenient way for these people to ...
(Date:9/19/2014)... VogueQueen.com has recently unveiled a ... ladies more beautiful at their weddings. The new range ... The company’s new products are made for the coming ... for all the global clients. , “The ... have ordered several items on its website. I'm very ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 Reduce bags ... ingredients made just for these issues in a serum. ... Haloxyl and Eyeliss," says Kathy Heshelow, founder of Sublime ... circulation and boosting collagen, to improve the eye area." ... serum for wrinkles, dark circles and bags at ...
(Date:9/18/2014)... 18, 2014 Defendants in more ... currently pending in Pennsylvania’s Philadelphia Court of Common ... on behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard ... 11th, the defendants maintain that circumstances surrounding the ... lawsuits have no connection to Pennsylvania. The filings ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says the Michael Brown Scenario Will Continue Without Swift Action in New Post 2Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:The Secret to Improving Under-Eye Skin: 30% Off Sale and Report on Ingredients Ends Tonight on the Face Whisperer® Advanced Eye Gel 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3
... study authored by a UT Southwestern Medical Center researcher has ... than a placebo in several other applications previously thought to ... of drugs used to increase red blood cells in patients ... in a study of 4,038 patients, it did little to ...
... ... therapy partner enlisting the public to send free treatment e-cards to the military and ... ... for a Healthier Life, today launched an online holiday program advancing the company,s commitment ...
... helps ID early breast cancer, 42 percent in study declined free ... high risk of breast cancer, an MRI can help detect malignancies ... 42 percent of such women in a new study said no ... wanted to have MRI, even though it was no cost to ...
... , ... saw exciting research progress, unprecedented opportunities on the horizon, and more ... economic and financial challenges, the National Multiple Sclerosis Society continues to ... provided over $33.5 million to support 345 new and ongoing projects ...
... MOINES, Iowa, Dec. 22 Palisade Systems, the leader in ... has completed internal certification of its PacketSure 7.6 service to ... services and software. , More and more companies are becoming ... recent article in eMarketer, close to 70 percent of small ...
... ... a comprehensive New Jersey anti-poverty charity, seeks year-end charitable contributions to meet an increasing need. ... Paterson, NJ (PRWEB) December ... Jersey during the current economic recession. By giving a charitable contribution to this trustworthy ...
Cached Medicine News:Health News:Anemia drug not helpful for kidney disease patients 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 2Health News:Prescription Audio Gives the Gift of Stress Relief This Holiday Season 3Health News:Many High-Risk Women Refuse Breast MRI 2Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 2Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 3Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 4Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 5Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 6Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 7Health News:National MS Society Continues to Propel Research Forward to End MS - Launches 2010 With Call for Research Grants to Pursue CCSVI Leads 8Health News:Palisade PacketSure Certified for Twitter and Facebook 2Health News:Eva's Village, a Paterson, New Jersey Anti-Poverty Charity, Seeks End of Year Charitable Contributions to Help Poor in a Troubled Economy 2Health News:Eva's Village, a Paterson, New Jersey Anti-Poverty Charity, Seeks End of Year Charitable Contributions to Help Poor in a Troubled Economy 3
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: